【热点】 成都先导与默沙东扩大合作签订DNA编码化合物库建设与筛选协议

如果您喜欢药智网推送的这篇文章

欢迎点赞和转发哦~

中国成都 2018年7月30日  成都先导药物开发有限公司（以下简称“成都先导”）宣布与默沙东（在美国和加拿大地区被称为默克）延长并扩大一项多年的研发合作与转让协议，双方将合作构建全新的DNA编码化合物库，以期筛选和发现潜在的独特小分子用于新药研发。基于此协议，两家公司的研发人员将利用成都先导DNA编码化合物这一先进技术平台，充分发挥其在新分子设计、合成及筛选方面的研发实力，为默沙东打造具有自主知识产权、多样化的DNA编码化合物库。此外，成都先导将利用旗下逾千亿化合物规模的DNA编码化合物库平台，针对默沙东关注的多个治疗靶点进行筛选。默沙东将为该项目提供研发支持，并对筛选得出的新颖先导化合物享有独家的后续研发权益。

成都先导董事长兼首席执行官李进博士表示“我们很高兴宣布与默沙东扩大合作，并拓展合作领域。我们将与默沙东的科学家们紧密合作，设计并建立默沙东专有的DNA编码化合物库以支持新一代药物筛选，解决未被满足的医疗需求。此次合作进一步巩固了成都先导在快速发展的DNA编码化合物库技术领域的领先地位，体现出公司以灵活的商业模式更好满足合作伙伴需求的专业实力。”

默沙东全球研发化学副总裁Emma Parmee博士表示“此前我们与成都先导合作利用其DNA编码化合物库技术拓展新药管线，双方建立了深厚的合作关系，希望通过此次扩大合作进一步加速新药研发进程。”

关于成都先导

成都先导是一家从事新药研发的生物技术公司，其总部位于中国成都，在美国设有子公司。成都先导已建立了一个独特的早期新药发现平台，即DNA编码化合物库设计合成与筛选技术。目前，成都先导基于数百种不同的骨架结构，已经完成逾千亿结构全新、具有多样性和类药性DNA编码化合物的合成，并且已有多个案例证实了其针对已知靶点和新兴靶点筛选苗头化合物的能力。成都先导已与50余家制药、生物技术企业以及研究机构建立合作，致力于发现、开发新的治疗方案。

更多信息请登录：www.hitgen.com

获取更多信息，请联系：

李进 博士

创始人、董事长兼首席执行官

成都先导药物开发有限公司

电话：+86 28 85197385(分机 8001)

Barry Morgan 博士

首席科学官

成都先导药物开发有限公司

电话：+1 508 840 9646

点击了解更多会议详情

2018年10月17日-19日，聚焦“创新、务实、合作”主题，“2018创新药物发现的前沿与实践国际高峰论坛”和“第8届DNA编码化合物库技术国际高峰论坛”在成都同期举办。大会汇集全球各界领军人物，围绕生物制药国家政策及行业趋势，新药研发新靶点及真实案例，深度聚焦DNA编码化合物库技术、AI、大数据等创新技术等前沿热门议题，结合主题演讲，One-on-One Partnering Meeting、项目路演，展台展示，墙报展示等多渠道，旨在搭建一个生物医药前瞻资讯和前沿思想交流分享的全球智慧平台，一个新药研发技术交流、整合的创新技术平台，同时成为一个对接创新资源、促进跨界商务合作的国际商业平台。

HitGen Extends and Expands Research Collaboration and License Agreement with MSD to Build and Screen Novel DNA-Encoded Libraries

Chengdu, China, July 30, 2018 HitGen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) in order to discover potential unique small molecule assets to be used in drug discovery and development. Through the collaboration, HitGen and MSD scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for MSD’s drug discovery efforts. In addition, HitGen will interrogate their own DELs, consisting of hundreds of billions of compounds, against a selected number of MSD’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to MSD for further research and development. MSD will support the research at HitGen. 

“We are delighted to announce the expansion and extension of this collaboration with MSD. Our scientists will continue to work closely together to design and build proprietary DELs to support the discovery of a new generation of medicines to address unmet clinical challenges. This collaboration reflects HitGen’s capabilities, expertise, and flexibility to develop business models to meet the needs of our collaboration partners, and provides insight into the success of our initial target-based collaboration” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

“This expanded collaboration builds upon the strong relationship we have developed with researchers at HitGen as we apply the DEL technology across our portfolio” said Dr. Emma Parmee, Vice President, Global Discovery Chemistry, MSD. 

About HitGen Ltd.

HitGen is an innovation driven life science company with headquarters and main research facilities based in Chengdu, China and with laboratory in USA.  HitGen has established a unique platform for drug discovery research. Our DNA encoded chemical libraries (DELs) contain more than 200 billion novel, diverse, drug-like compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry based on proven results for identifying small molecule leads against targets from both known and unprecedented protein classes.  HitGen is collaborating with multiple pharmaceutical, biotech and agrochemical companies, and academic research institutes to discover and develop the therapeutics of the future.

For further information, please contact

Dr. Jin Li, Founder, Chairman & CEO， HitGen Ltd. Tel: +86 28 85197385

Dr. Barry Morgan, Chief Scientific Officer，HitGen Ltd. Tel: +1 508 840 9646